Precision Medicine: Maximising Treatment Benefit for Rheumatoid Arthritis Patients

This symposium took place on 9th June 2016 as part of the European League Against Rheumatism (EULAR) Congress 2016 in London, UK

Chairperson: Ernest Choy1
Speakers: Ernest Choy,1 Eric Ruderman,2 Cem Gabay,3 Georg Schett4

1. Cardiff University School of Medicine and University Hospital of Wales, Cardiff, UK
2. Northwestern University Feinberg School of Medicine and Northwestern Medical Group, Chicago, Illinois, USA
3. University of Geneva School of Medicine and University Hospitals of Geneva, Geneva, Switzerland
4. University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany

Disclosure: Prof Ernest Choy has received research grants and served as a member of advisory boards and speaker bureaus of Abbott Laboratories, Allergan, AstraZeneca, BMS, Boehringer Ingelheim, Chelsea Therapeutics, Chugai Pharma, Daiichi Sankyo, Eli Lilly, Ferring Pharmaceutical, GSK, ISIS, Jazz Pharmaceuticals, MedImmune, Merrimack Pharmaceutical, MSD, Novimmune, Novartis, Pfizer, Pierre Fabre Medicament, Regeneron, Roche, Sanofi-Aventis, Schering Plough, Synovate, and UCB. Prof Eric Ruderman has received consultancy fees from AbbVie, Amgen, Roche/Genentech, Janssen, Eli Lilly, Novartis, Pfizer, and Seattle Genetics, and has received research grants from Amgen and Pfizer. Prof Cem Gabay has received research grants and consultancy fees from Roche, AbbVie, Pfizer, BMS, MSD, UCB, Sanofi, Regeneron, Actelion, Novartis, AB2 Bio, and Debiopharm. Prof Georg Schett has received consultancy fees from AstraZeneca, BMS, Celgene, Chugai, Eli Lilly, Novartis, and Roche.
Acknowledgements: Writing assistance was provided by Dr Alice Lale, Health Interactions Ltd.
Support: The symposium was organised and funded by Roche and Chugai. All authors received honoraria for preparation and delivery of their presentations. Writing assistance for this article was funded by Roche and Chugai; however, the views and opinions expressed are those of the authors and not necessarily those of Roche and Chugai.
Citation: EMJ Rheumatol. 2016;3[1]:57-65.

Meeting Summary

This educational symposium was opened by Prof Ernest Choy, who introduced the concept of precision medicine and highlighted the importance of integrating current research with clinical experience to guide treatment decisions. He also highlighted the growing recognition of precision medicine within rheumatology. Prof Eric Ruderman then explored current medical views around the use of glucocorticoids (GCs) in rheumatoid arthritis (RA), revealing how uncertainty over the true risk/benefit ratio of these agents means that their impact as part of patient care must be further studied. Next, Prof Cem Gabay reviewed the evidence from clinical trials, registries, and real-world studies supporting biologic monotherapy as a treatment strategy in patients for whom methotrexate (MTX) is inappropriate. Prof Georg Schett then considered how current biomarker research might influence patient care in the future, especially with respect to assessing disease course and treatment responses in RA. Finally, Prof Choy presented a series of patient case studies, featuring practical issues faced by rheumatologists in the clinic, and drew upon the themes of the preceding presentations to highlight the value of a precision medicine approach to RA. Following closing remarks from Prof Choy, a lively discussion session enabled the audience to ask the expert panel about the wider clinical implications of their views.

The pivotal role of IL-6 in RA5 was explored in a video at the beginning of the session, which highlighted the importance of further research in this area (available to view here).

Download (PDF, 145KB)

Comments are closed.